Published in Am J Hematol on June 01, 2008
Resolvins and protectins in inflammation resolution. Chem Rev (2011) 3.09
Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ Res (2010) 1.89
Resolvin E1, an EPA-derived mediator in whole blood, selectively counterregulates leukocytes and platelets. Blood (2008) 1.66
(n-3) fatty acids and cardiovascular health: are effects of EPA and DHA shared or complementary? J Nutr (2012) 1.64
Novel anti-inflammatory--pro-resolving mediators and their receptors. Curr Top Med Chem (2011) 1.61
Rescue and repair during photoreceptor cell renewal mediated by docosahexaenoic acid-derived neuroprotectin D1. J Lipid Res (2010) 1.45
Specialized proresolving mediators enhance human B cell differentiation to antibody-secreting cells. J Immunol (2012) 1.20
Role of platelets in neuroinflammation: a wide-angle perspective. J Neuroinflammation (2010) 1.11
Cutting edge: Parathyroid hormone facilitates macrophage efferocytosis in bone marrow via proresolving mediators resolvin D1 and resolvin D2. J Immunol (2014) 0.98
Fish oil and inflammatory status alter the n-3 to n-6 balance of the endocannabinoid and oxylipin metabolomes in mouse plasma and tissues. Metabolomics (2012) 0.97
Resolvin E1 and chemokine-like receptor 1 mediate bone preservation. J Immunol (2012) 0.92
Maternal dietary omega-3 fatty acid intake increases resolvin and protectin levels in the rat placenta. J Lipid Res (2013) 0.92
15-lipoxygenase metabolites of docosahexaenoic acid inhibit prostate cancer cell proliferation and survival. PLoS One (2012) 0.91
Dietary polyunsaturated fatty acids and inflammation: the role of phospholipid biosynthesis. Int J Mol Sci (2013) 0.88
The specialized proresolving mediator 17-HDHA enhances the antibody-mediated immune response against influenza virus: a new class of adjuvant? J Immunol (2014) 0.88
The association of red blood cell n-3 and n-6 fatty acids with bone mineral density and hip fracture risk in the women's health initiative. J Bone Miner Res (2013) 0.88
The omega-6 arachidonic fatty acid, but not the omega-3 fatty acids, inhibits osteoblastogenesis and induces adipogenesis of human mesenchymal stem cells: potential implication in osteoporosis. Osteoporos Int (2012) 0.86
Lipoxin A₄ modulates adaptive immunity by decreasing memory B-cell responses via an ALX/FPR2-dependent mechanism. Eur J Immunol (2014) 0.84
Bioactive lipid mediators in polycystic kidney disease. J Lipid Res (2013) 0.82
The role of polyunsaturated ω-3 fatty acid eicosapentaenoic acid-derived resolvin E1 (RvE1) in bone preservation. Crit Rev Immunol (2014) 0.79
Supplementation with fish oil and genistein, individually or in combination, protects bone against the adverse effects of methotrexate chemotherapy in rats. PLoS One (2013) 0.78
Inflammation resolution: does the bone marrow have a say? Am J Hematol (2008) 0.75
Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature (2007) 6.53
Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med (2005) 5.00
TLR11 activation of dendritic cells by a protozoan profilin-like protein. Science (2005) 4.86
Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J Biol Chem (2003) 4.58
Molecular circuits of resolution: formation and actions of resolvins and protectins. J Immunol (2005) 4.30
Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc Natl Acad Sci U S A (2004) 4.28
Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions. Nat Med (2010) 4.23
Infection regulates pro-resolving mediators that lower antibiotic requirements. Nature (2012) 4.04
Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J Biol Chem (2003) 3.80
International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family. Pharmacol Rev (2009) 3.65
Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc Natl Acad Sci U S A (2010) 3.60
Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell (2012) 3.54
A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest (2005) 3.44
Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci U S A (2005) 3.32
Resolvin D1 and its aspirin-triggered 17R epimer. Stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation. J Biol Chem (2007) 3.28
Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature (2009) 3.27
Resolvin E1 regulates interleukin 23, interferon-gamma and lipoxin A4 to promote the resolution of allergic airway inflammation. Nat Immunol (2008) 3.15
Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A(4). Nat Med (2002) 2.94
Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J Immunol (2007) 2.83
The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo. Pharmacol Rev (2006) 2.80
Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB J (2008) 2.78
Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor. Nat Med (2002) 2.75
Resolvin D series and protectin D1 mitigate acute kidney injury. J Immunol (2006) 2.75
Resolvin E1 regulates inflammation at the cellular and tissue level and restores tissue homeostasis in vivo. J Immunol (2007) 2.66
Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-resolving mediators. Blood (2012) 2.37
Apoptotic neutrophils and T cells sequester chemokines during immune response resolution through modulation of CCR5 expression. Nat Immunol (2006) 2.37
Resolvin E2: identification and anti-inflammatory actions: pivotal role of human 5-lipoxygenase in resolvin E series biosynthesis. Chem Biol (2006) 2.36
Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. Proc Natl Acad Sci U S A (2004) 2.34
Rapid appearance of resolvin precursors in inflammatory exudates: novel mechanisms in resolution. J Immunol (2008) 2.32
Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis. Proc Natl Acad Sci U S A (2006) 2.31
Lipid mediators in innate immunity against tuberculosis: opposing roles of PGE2 and LXA4 in the induction of macrophage death. J Exp Med (2008) 2.17
Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness. J Immunol (2007) 2.11
Resolvins and protectins in the termination program of acute inflammation. Trends Immunol (2007) 2.06
Lipid mediator-induced expression of bactericidal/ permeability-increasing protein (BPI) in human mucosal epithelia. Proc Natl Acad Sci U S A (2002) 2.01
Resolvin D3 and aspirin-triggered resolvin D3 are potent immunoresolvents. Chem Biol (2013) 1.96
The docosatriene protectin D1 is produced by TH2 skewing and promotes human T cell apoptosis via lipid raft clustering. J Biol Chem (2005) 1.96
Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation. J Clin Invest (2011) 1.92
Diabetes promotes an inflammatory macrophage phenotype and atherosclerosis through acyl-CoA synthetase 1. Proc Natl Acad Sci U S A (2012) 1.91
Anti-inflammatory actions of lipoxin A4 and aspirin-triggered lipoxin are SOCS-2 dependent. Nat Med (2006) 1.90
Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ Res (2010) 1.89
MicroRNAs in resolution of acute inflammation: identification of novel resolvin D1-miRNA circuits. FASEB J (2010) 1.87
15-epi-lipoxin A4 inhibits myeloperoxidase signaling and enhances resolution of acute lung injury. Am J Respir Crit Care Med (2009) 1.81
Diversity of lipid mediators in human adipose tissue depots. Am J Physiol Cell Physiol (2013) 1.80
Specialized pro-resolving lipid mediators in the inflammatory response: An update. Biochim Biophys Acta (2010) 1.72
Saturated-efferocytosis generates pro-resolving CD11b low macrophages: modulation by resolvins and glucocorticoids. Eur J Immunol (2010) 1.70
Metabolomics-lipidomics of eicosanoids and docosanoids generated by phagocytes. Curr Protoc Immunol (2011) 1.69
Unesterified docosahexaenoic acid is protective in neuroinflammation. J Neurochem (2013) 1.68
Resolvin E1 promotes mucosal surface clearance of neutrophils: a new paradigm for inflammatory resolution. FASEB J (2007) 1.67
Resolvin D1 limits polymorphonuclear leukocyte recruitment to inflammatory loci: receptor-dependent actions. Arterioscler Thromb Vasc Biol (2012) 1.67
International Union of Pharmacology XXXVII. Nomenclature for leukotriene and lipoxin receptors. Pharmacol Rev (2003) 1.66
Resolvin E1, an EPA-derived mediator in whole blood, selectively counterregulates leukocytes and platelets. Blood (2008) 1.66
Plasticity of leukocytic exudates in resolving acute inflammation is regulated by MicroRNA and proresolving mediators. Immunity (2013) 1.64
Emerging roles of resolvins in the resolution of inflammation and pain. Trends Neurosci (2011) 1.60
Resolving TRPV1- and TNF-α-mediated spinal cord synaptic plasticity and inflammatory pain with neuroprotectin D1. J Neurosci (2011) 1.58
The resolution of inflammation. Nat Rev Immunol (2012) 1.58
Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-kappa B and AP-1 activation, and IL-8 gene expression in human leukocytes. Proc Natl Acad Sci U S A (2002) 1.54
Small-molecule screen identifies reactive oxygen species as key regulators of neutrophil chemotaxis. Proc Natl Acad Sci U S A (2010) 1.53
Aspirin-triggered lipoxin A4 and B4 analogs block extracellular signal-regulated kinase-dependent TNF-alpha secretion from human T cells. J Immunol (2003) 1.52
Cutting edge: Humanized nano-proresolving medicines mimic inflammation-resolution and enhance wound healing. J Immunol (2011) 1.52
Resolvin E1 metabolome in local inactivation during inflammation-resolution. J Immunol (2008) 1.52
Simultaneous lipidomic analysis of three families of bioactive lipid mediators leukotrienes, resolvins, protectins and related hydroxy-fatty acids by liquid chromatography/electrospray ionisation tandem mass spectrometry. Rapid Commun Mass Spectrom (2008) 1.51
Epoxyeicosatrienoic acid agonist rescues the metabolic syndrome phenotype of HO-2-null mice. J Pharmacol Exp Ther (2009) 1.51
Resolvin E1 receptor activation signals phosphorylation and phagocytosis. J Biol Chem (2009) 1.50
New endogenous anti-inflammatory and proresolving lipid mediators: implications for rheumatic diseases. Nat Clin Pract Rheumatol (2007) 1.48
Resolvin D1 and aspirin-triggered resolvin D1 promote resolution of allergic airways responses. J Immunol (2012) 1.48
Aspirin-triggered lipoxin and resolvin E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis. Am J Pathol (2010) 1.47
Metabolic inactivation of resolvin E1 and stabilization of its anti-inflammatory actions. J Biol Chem (2006) 1.45
Rescue and repair during photoreceptor cell renewal mediated by docosahexaenoic acid-derived neuroprotectin D1. J Lipid Res (2010) 1.45
Resolution of acute inflammation in the lung. Annu Rev Physiol (2013) 1.42
Anti-angiogenesis effect of the novel anti-inflammatory and pro-resolving lipid mediators. Invest Ophthalmol Vis Sci (2009) 1.42
Anesthetics impact the resolution of inflammation. PLoS One (2008) 1.42
Melanoma growth is reduced in fat-1 transgenic mice: impact of omega-6/omega-3 essential fatty acids. Proc Natl Acad Sci U S A (2006) 1.42
The novel 13S,14S-epoxy-maresin is converted by human macrophages to maresin 1 (MaR1), inhibits leukotriene A4 hydrolase (LTA4H), and shifts macrophage phenotype. FASEB J (2013) 1.40
Differential trafficking of saccharidic probes following aspirin in clinical tests of intestinal permeability in young healthy women. Clin Exp Pharmacol Physiol (2014) 1.40
Anti-inflammatory circuitry: lipoxin, aspirin-triggered lipoxins and their receptor ALX. Prostaglandins Leukot Essent Fatty Acids (2005) 1.39
Resolvin D1 receptor stereoselectivity and regulation of inflammation and proresolving microRNAs. Am J Pathol (2012) 1.37
Rainbow trout (Oncorhynchus mykiss) brain cells biosynthesize novel docosahexaenoic acid-derived resolvins and protectins-Mediator lipidomic analysis. Prostaglandins Other Lipid Mediat (2005) 1.36
Lipoxins and new lipid mediators in the resolution of inflammation. Curr Opin Pharmacol (2006) 1.35
The opportunistic pathogen Pseudomonas aeruginosa carries a secretable arachidonate 15-lipoxygenase. Proc Natl Acad Sci U S A (2004) 1.33
Resolvin D1, protectin D1, and related docosahexaenoic acid-derived products: Analysis via electrospray/low energy tandem mass spectrometry based on spectra and fragmentation mechanisms. J Am Soc Mass Spectrom (2006) 1.33
Lipoxins and aspirin-triggered lipoxin inhibit inflammatory pain processing. J Exp Med (2007) 1.32
Resolvin D1 and resolvin D2 govern local inflammatory tone in obese fat. J Immunol (2012) 1.31
Leukotriene B4 and lipoxin A4 are regulatory signals for neural stem cell proliferation and differentiation. FASEB J (2006) 1.31
Regulation of inflammation in cancer by eicosanoids. Prostaglandins Other Lipid Mediat (2011) 1.31
Aspirin-triggered lipoxins override the apoptosis-delaying action of serum amyloid A in human neutrophils: a novel mechanism for resolution of inflammation. J Immunol (2007) 1.30
Human ALX receptor regulates neutrophil recruitment in transgenic mice: roles in inflammation and host defense. FASEB J (2003) 1.29
Impaired phagocytosis in localized aggressive periodontitis: rescue by Resolvin E1. PLoS One (2011) 1.29
A novel anti-inflammatory and pro-resolving role for resolvin D1 in acute cigarette smoke-induced lung inflammation. PLoS One (2013) 1.28
Resolvin D2 is a potent endogenous inhibitor for transient receptor potential subtype V1/A1, inflammatory pain, and spinal cord synaptic plasticity in mice: distinct roles of resolvin D1, D2, and E1. J Neurosci (2011) 1.27
Lipid and lipid mediator profiling of human synovial fluid in rheumatoid arthritis patients by means of LC-MS/MS. Biochim Biophys Acta (2012) 1.27
Novel lipid mediator regulators of endothelial cell proliferation and migration: aspirin-triggered-15R-lipoxin A(4) and lipoxin A(4). J Pharmacol Exp Ther (2002) 1.27
Neuroprotectin D1/protectin D1 stereoselective and specific binding with human retinal pigment epithelial cells and neutrophils. Prostaglandins Leukot Essent Fatty Acids (2010) 1.26
Conjunctival goblet cell secretion stimulated by leukotrienes is reduced by resolvins D1 and E1 to promote resolution of inflammation. J Immunol (2011) 1.23
Specialized proresolving mediator targets for RvE1 and RvD1 in peripheral blood and mechanisms of resolution. Biochem J (2011) 1.23
Thromboxane A2 is a key regulator of pathogenesis during Trypanosoma cruzi infection. J Exp Med (2007) 1.21
Specialized proresolving mediators enhance human B cell differentiation to antibody-secreting cells. J Immunol (2012) 1.20